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studies on iron metabolism and related disorders, the results of
which have profoundly changed our view of human diseases
associated with excess of iron, iron deﬁciency or iron misdistribu-
tion. Not only has new light been shed on the pathogenesis of
these disorders, but therapeutic applications from these advances
are now foreseen. The notion that hepcidin excess or deﬁciency
may contribute to the dysregulation of iron homeostasis in
hereditary and acquired iron disorders raises the possibility that
hepcidin-lowering or enhancing agents may be an effective strat-
egy for curing the main consequences of hepcidinopathies, ane-
mia or iron overload, respectively. Experimental pre-clinical
and clinical studies have shown that hepcidin antibodies, ago-
nists or antagonists, cytokine receptor antibodies and small-mol-
ecules that modify hepcidin expression also reverse iron
abnormalities in vivo, in a number of disease models. While
future studies addressing safety and long-term efﬁcacy of hepci-
din-targeted treatments will clarify risks and beneﬁts, a new era
has begun based on the treatment of disorders of iron homeosta-
sis through the modulation of its regulatory hormone, hepcidin.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
In 2000, a peptide was isolated from human blood ultraﬁltrate
and named LEAP-1 for liver expressed antimicrobial peptide [1].
In 2001, the same peptide was found in human urine [2] and
the cDNA of its murine homolog cloned from the mouse liver
[3] and renamed hepcidin. The 25mer peptide exerted some anti-
bacterial and antifungal effects, and the protein itself was classi-
ﬁed—along with the thionins and the defensins—as a member of
the cysteine-rich, cationic, antimicrobial peptide family. At the
time, we all thought we had just one more antimicrobial peptide
to deal with. No one could predict how much that small peptideJournal of Hepatology 20
Abbreviations: HC, hemochromatosis; TfR2, transferrin receptor 2; HAMP, hep-
cidin gene; HJV, hemojuvelin; Tf, transferrin; FPN, ferroportin; LEAP-1, liver ex-
pressed antimicrobial protein; BMPs, bone morphogenetic proteins; RGMs,
repulsive guidance molecules; RGMs, transmembrane serine protease 6 gene;
sHJV, soluble form of HJV; GDF15, growth differentiation factor 15; TWSG1, tw-
isted gastrulation protein homolog 1; transferrin receptor 1.
Received 29 June 2010; received in revised form 3 August 2010; accepted 19 August
2010
q Disclosure: No conﬂict of interest to disclose.
E-mail address: antonello.pietrangelo@unimore.itPigeon et al. [3] were the ﬁrst to link hepcidin to iron, and shortly
thereafter, knockout and transgenic mouse studies revealed that
hepcidin is in fact the principal down-regulator of iron trafﬁc
directed toward the bloodstream from the external environment
(i.e., the intestinal lumen or, for the fetus, maternal blood) and
from the body storage sites [4–6]. Iron is a critical nutrient that
is continuously recycled within the erythron compartment: the
unavoidable daily losses are actively compensated by extracting
1–2 mg of iron from diet [7]. We also know from pioneering iron
kinetic studies performed in the 1950s that iron uptake, storage,
and utilization are meticulously coordinated [8]. It had been
hypothesized that signals from storage compartments (mainly
hepatocytes and macrophages) and utilization sites (primarily
the bone marrow)—historically referred to as ‘‘store” and ‘‘ery-
throid” regulatory signals [9]—are transmitted to a central con-
trol site that would then dictate the amount of iron released
into the bloodstream and delivered to the bone marrow. We
now know that that the central control site of iron trafﬁc is the
liver and its effector is the hormone peptide hepcidin [10].
The discovery of hepcidin has triggered a virtual explosion of
studies, the results of which have profoundly changed our view of
diseases of iron metabolism and beyond. Not only has new light
been shed on the pathogenesis of iron disorders, but new scenar-
ios for diagnosis and treatment are now foreseen. The therapeutic
implications of hepcidin discovery are the subject of this article.Hepcidin synthesis, function, and regulation
Hepcidin is synthesized in the liver as a 84 amino acid pre-pro-
peptide containing a typical N-terminal 24 amino acid endoplas-
mic reticulum targeting signal sequence, and a consensus furin
cleavage site immediately preceding the C-terminal 25 amino
acid bioactive peptide [2,3,11]. In addition to prohepcidin and
hepcidin-25, 22, and 20 carboxy terminal amino acid forms of
hepcidin are found in the circulation and/or urine, but hepci-
din-25 is the bioactive form of hepcidin, whereas the other forms
have little or no biological activity.
Hepcidin likely evolved in humans as part of the innate
immune defense to prevent invading pathogens from using iron
sources to grow and proliferate. In fact, it is the main circulating
inhibitor of iron ﬂux from enterocytes, hepatocytes, macro-
phages, and placental cells into the bloodstream. Hepcidin pro-
duces these effects by binding to ferroportin (FPN), the main
cellular iron-exporter in mammals. Independently identiﬁed in11 vol. 54 j 173–181
Review
2000 by three different laboratories [12–14], FPN (previously
referred to as IREG1 or MTP1) is a multi-domain transmembrane
protein encoded by the SLC40A1 gene. It is mainly expressed by
the cells that play key roles in mammalian iron metabolism,
including placental syncytiotrophoblasts, duodenal enterocytes,
hepatocytes, and reticuloendothelial macrophages. As a result
of its interaction with circulating hepcidin, FPN is internalized
and degraded, thereby diminishing the cells’ ability to transfer
iron to the plasma compartment [15]. Through its N-terminus
domain, hepcidin binds to the extracellular region of FPN, causing
Jak2-mediated tyrosine phosphorylation at residues 302 and 303
in FPN’s cytosolic loop. FPN is then internalized, dephosphoryl-
ated, ubiquitinated, and ultimately degraded in the late endo-Fig. 1. Signals and pathways controlling hepcidin expression in the liver. Hepcidin r
mainly linked to the erythroid activity. The iron-sensing process involves the local iron-
subsequent assembly of a membrane-associated hetero-tetrameric signaling complex,
activates a common signal transduction cascade involving the phosphorylation of intrace
the cytoplasm. The resulting complex then translocates to the nucleus, where it activate
receptor for RGM, has been proposed to stabilize HJV, and participate in HJV shedding.
membrane-anchored counterpart (either by sequestering free ligands or by displacing H
hepcidin expression. SMAD7, which is stimulated by iron, seems to attenuate the signal
protease 6, TMPRSS6), inhibits hepcidin expression, most likely by cleaving HJV. Normal H
might constitute a functional sensing unit responsible for conveying the iron signal to he
which stimulates hepcidin transcription through STAT3, although a possible contribution
binding protein H (CREBH), has been recently implicated in the transcriptional activatio
response to inﬂammatory stimuli in vivo. Inhibitory signals for hepcidin transcription i
derived from maturing erythroblasts in the bone marrow, such as growth differentiation
details).
174 Journal of Hepatology 201some/lysosome compartment [16,17]. Later, if iron is needed in
the bone marrow for hemoglobin synthesis, hepcidin production
declines, FPN is re-expressed at the cell surface, and iron export
to the bloodstream resumes. This negative-feedback mechanism
keeps circulating iron levels within a range that will satisfy the
body’s erythropoietic needs without provoking oxidative damage
to body cells.
Hepcidin responds to stimulatory and inhibitory signals. The
former include inﬂammatory stimuli and iron load, but also stress
signals arising within the cell, such as those related to endoplas-
mic reticulum (ER) stress [18,19] (Fig. 1). The latter mostly orig-
inate in the erythroid compartment and are probably
hierarchically dominant. In fact, maintaining a constant sourceesponds to stimulatory signals, such as iron and cytokines, or inhibitory signals,
induced production of bone morphogenic proteins (BMPs), such as BMP6, and the
composed of two type I and two type II serine threonine kinase receptors. This
llular receptor-activated Smad1, Smad5 and Smad8, which interact with Smad4 in
s transcription of the hepcidin gene (see text for details). Neogenin, a membrane
The soluble form of HJV (sHJV), is thought to compete for BMP binding with its
JV from its BMP-R binding site), thereby providing iron-sensitive modulation of
for hepcidin activation. The serine protease/matriptase 2 (transmembrane serine
FE interacts with TfR1, and probably also with TfR2. Together, these three proteins
pcidin. A key mediator of hepcidin response to inﬂammation is interleukin 6 (IL-6)
of the BMP/SMD pathway has also been evoked. The C-AMP responsive element
n of hepcidin during ER stress and seems also to partially contribute to hepcidin
nclude hypoxic inducible factor (HIF), erythropoietin (Epo), or circulating factors
factor (GDF15) and twisted gastrulation protein homolog 1 (TWSG1) (see text for
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of iron for hemoglobin synthesis (around 20 mg a day) is a top
priority for the human body, so when demand increases in the
erythroid compartment, hepatic hepcidin output has to be
decreased. Hypoxia, anemia, and iron deﬁciency all inhibit hepci-
din synthesis [20] and several putative mediators have been pro-
posed: hypoxic inducible factor [21], erythropoietin [22], or
circulating factors derived from maturing erythroblasts in the
bone marrow, such as growth differentiation factor 15 (GDF15)
and twisted gastrulation protein homolog 1 (TWSG1) [23,24]
(Fig. 1). The serine protease/matriptase 2 [25] (transmembrane
serine protease 6 gene, TMPRSS6), inhibits hepcidin likely by
cleaving hemojuvelin (HJV), a membrane-bound protein that pro-
motes hepcidin signaling in hepatocytes (see below) (Fig. 1) [26].
Inhibitory signals include those arising during infection and
inﬂammatory states and iron itself. Inﬂammation readily induces
hepcidin expression [3,20]. A key player in hepcidin activation
during inﬂammation is interleukin 6 (IL-6) [27], which activates
hepcidin transcription through STAT3 [28–30], although an intact
BMP-SMAD signaling pathway seems to be also required for such
activity [31–34]. Pro-inﬂammatory cytokines and LPS also induce
endoplasmic reticulum (ER) stress and activation of the C-AMP
responsive element binding protein H (CREBH), recently involved
in the regulation of acute phase proteins in the liver [35]. CREBH
has been recently implicated in the transcriptional activation of
hepcidin during ER stress and also seems to partially contribute
to hepcidin response to inﬂammatory stimuli in vivo [18]. Hepci-
din is also produced in monocytes/macrophages [36] and is
induced in these cells by LPS and certain bacterial pathogens
through Toll like receptors and possibly also the IL-6/STAT3 path-
way. It might function through an autocrine mechanism to alter
iron trafﬁc locally during pathogen invasion [37]. Recently, a
new function for hepcidin in modulating acute inﬂammatory
responses has been proposed. De Domenico et al. [38] have
shown that hepcidin-treatment of macrophages directly activates
the transcription factor Stat3 through Jak2-mediated phosphory-
lation, resulting in a transcriptional anti-inﬂammatory response.
Most notably, hepcidin pretreatment protected mice from a
lethal dose of LPS and hepcidin-knockout mice could be rescued
from LPS toxicity by injection of hepcidin [38].
Iron is a main stimulus for hepcidin. ‘‘Iron-sensing” occurs
through a complex multiprotein system at the hepatocyte plasma
membrane (Fig. 1) that involves bone morphogenetic proteins
(BMPs) and their receptors as well as a number of ancillary pro-
teins. Members of the TGF-b superfamily [39], BMP ligands trig-
ger intracellular signaling through downstream effectors, the
Smad proteins, which translocate to the nucleus and activate
the expression of various genes, including HAMP. The timing,
location, and speciﬁc downstream effects of BMP signaling are
controlled by a network of regulatory proteins, which includes
a family of BMP co-receptors known as the repulsive guidance
molecules (RGMs). The RGM providing speciﬁcity to the iron sig-
nal in the liver is RGMc, also known as hemojuvelin (HJV). In
2004, mutations involving the HJV gene were identiﬁed as the
most common cause of juvenile hemochromatosis (HC) [40].
The putative full-length protein (426 amino acids) encoded by
HJV includes a C-terminal glycosylphosphatidylinositol anchor,
which indicates that it can be present in either a soluble or
cell-associated form. As shown in Fig. 1, the latter form is part
of the BMP signaling complex whose activation results in the
expression of hepcidin. The soluble form of HJV (sHJV), whose
release (HJV shedding) is inhibited by increasing extracellularJournal of Hepatology 201concentrations of iron, is thought to compete with its mem-
brane-anchored counterpart for BMP binding [41], although it is
unclear whether and to what extent this process operates
in vivo to regulate iron homeostasis (Fig. 1). Neogenin, a member
of the DCC (deleted in colorectal cancer) family of tumor suppres-
sor molecules has been identiﬁed as a receptor for RGMs, and
appears to interact with HJV [42,43]. However, its role in HJV
biology and hepcidin synthesis is still controversial [44].
Recently, it has been suggested that neogenin inhibits HJV shed-
ding and formation of sHJV: the liver of neogenin-mutant mice
exhibits reduced BMP signaling, low levels of hepcidin, and iron
overload [45].
Iron has been shown to increase hepatic BMP signaling [32],
while the administration of BMP increases hepcidin expression
and reduces serum iron [31,33,46]. Since Smad7 [47] is co-regu-
lated with hepcidin by BMPs, and SMAD7 over-expression has
been found to abrogate BMP-mediated activation of hepcidin, this
protein might operate as an intracellular negative-feedback regu-
lator of hepcidin synthesis [48] (Fig. 1). Various BMPs have proved
to be capable of stimulating hepcidin synthesis in vitro, but a par-
ticularly important role is emerging for BMP6 [49,50], which can
physically interact with soluble HJV and increases hepcidin
expression and reduces serum iron levels in mice [49]. Notably,
Bmp6-null mice exhibit an hemochromatosis-like phenotype
characterized by reduced hepcidin expression and tissue iron
overload. [49,50] These data point to BMP6 as an endogenous reg-
ulator of hepcidin expression and iron metabolism in vivo.
The iron-sensing process also seems to involve two other pro-
teins, whose loss, like that of HJV, has been linked to human HC:
HFE and transferrin receptor 2 (TfR2). HFE is a major histocom-
patibility class-I-like protein that interacts with transferrin
receptor 1 (TfR1) [51], a type II transmembrane glycoprotein that
mediates uptake of transferrin-bound iron, particularly by ery-
throid cells. It now looks as if HFE or the TfR1-HFE complex might
play some role in the regulation of hepcidin expression. The func-
tional loss of HFE in mice [52] and humans [53,54] has been
shown to reduce hepcidin synthesis, but more recent ﬁndings
indicate that hepcidin expression is clearly down-regulated by
hepatocyte-speciﬁc deletion of Hfe [55]. In fact, HFE loss seems
to be associated with blunted signaling responses to BMP6, a
key regulator of hepcidin, in vitro and in vivo [56,57]. This sug-
gests that HFE might be necessary for an optimal response to
low endogenous basal levels of BMPs, which is believed to act
in an autocrine or paracrine fashion in the liver. TfR2, unlike
TfR1, is highly expressed in the liver, and its expression is unaf-
fected by the intracellular iron status. Moreover, functional loss
of TfR2—in mice [58] and in humans [59]—is associated with
decreased hepcidin expression. One possibility is that it operates
in the pathway discussed above for HFE (or in a parallel pathway
of its own), facilitating the BMP/SMAD signaling that activates
hepcidin expression (Fig. 1). Another possibility is that TfR2,
which is also able to interact with HFE [60–63], forms an iron-
sensing complex that modulates hepcidin expression in response
to blood levels of diferric transferrin [61,64].
In summary, hepcidin, a small hormone peptide, is constitu-
tively produced by the liver to maintain plasma iron levels within
a narrow physiologic range. To do so it senses a variety of phys-
iologic and pathophysiologic stimuli, mainly the erythropoietic
activity and inﬂammatory states, which tend to alter blood iron
levels, and responds by inhibiting the main iron-exporter in
mammals, ferroportin (Box 1).1 vol. 54 j 173–181 175
ReviewGDF15: growth differentiation factor 15; TWSG1: twisted gastru-
lation protein homolog 1.Targeting the hepcidin–ferroportin axis to cure human iron
disorders
The blood concentrations of iron must be kept constant as both
iron deﬁciency or iron excess may be a cause of disability and dis-
ease (Table 1). Recently, it has been recognized iron also plays aTable 1. Human disorders associated with or caused by disturbances of iron metabo
1Although the ferroportin disease is characterized by systemic iron overload, in the clas
dothelial macrophage system. 2In Friedreich’s ataxia loss of frataxin leads to mitochond
176 Journal of Hepatology 201role in other disorders that are associated with ‘‘iron-mis-distri-
bution” [65], within certain cell types (e.g., macrophages in ane-
mia of chronic disease) or even within cell organelles
(mitochondria in Friedreich’s ataxia) [66]. Finally, conditions exist
where iron preferentially accumulates in certain organs mostly
following necro-inﬂammatory events or caused by locally altered
iron trafﬁc (e.g., the liver in chronic viral hepatitis or the brain in
neurodegenerative disorders). In strict terms, the latter disorders
may not all qualify as true iron overload states, as total body iron
content may not be increased. Nevertheless, the impact on cell
damage and organ disease may be extremely high even in the
presence of mild iron overload, as any excess iron may fuel oxida-
tive stress and affect signaling pathways important for the patho-
genesis of that speciﬁc condition (e.g., chronic liver disorders).
When considering the broad range of iron-related disorders, there
is evidence for a pathogenic involvement of hepcidin/ferroportin
in a number of them, either hereditary (such as HC, the ferroportin
disease, IRIDA) or secondary to other causes (such as inﬂamma-
tion in anemia of chronic disease, ACD) or inefﬁcient erythropoi-
esis in thalassemia intermedia and other hereditary anemias)
(Table 1)(Fig. 2). Recently, experimental evidence has been pro-
vided for acquired factors, such as alcohol consumption [67,68]
or chronic viral hepatitis [69], being also able to decrease hepcidin
transcription and cause hepatic iron overload.Disorders potentially treatable with hepcidin agonists
In general, based on what we have learned on hepcidin biology
and regulation, we can predict that any genetic (or acquired)
factor that decreases hepcidin synthesis/activity will lead to anlism.
sic form of the disorder, iron excess may be exclusively found in the reticuloen-
rial iron accumulation, cell damage and organ (mainly brain) disorders.
1 vol. 54 j 173–181
Fig. 2. Hepcidin in the pathogenesis of human hereditary and acquired iron disorders. Abnormal hepcidin regulation is responsible for iron disturbances in
paradigmatic human disorders characterized by hepcidin deﬁciency (HFE-hemochromatosis and thalassemia) or hepcidin excess (anemia of chronic disease or anemia of
inﬂammation). The Figure depicts the liver, as the main site of hepcidin production, and the macrophage, a site for hepcidin activity highly expressing ferroportin, the
hepcidin-target. HFE-Hemochromatosis: In HFE-HC, functional loss of HFE due to the C282Y mutation, leads to impaired BMP/SMAD signaling and hepcidin attenuated
transcriptional activity (see text for details). The effect of inadequate levels of circulating hepcidin leads to unchecked iron-export by ferroportin in the macrophage,
responsible for progressive plasma iron load, tissue iron accumulation and disease. Thalassemia: In hereditary anemias associated with inefﬁcient erythropoiesis, such as
thalassemia at early pre-transfusion stages, erythroid factors induced by inefﬁcient erythropoiesis (such as GDF15 and TWSG1) inhibits hepcidin transcription, and cause, in
analogy with HFE-HC, hepcidin deﬁciency and unrestricted iron release from macrophages toward the bloodstream. Anemia of inﬂammation: During inﬂammatory states
or infection, pathogen by-products may lead to cytokine overproduction, particularly from macrophages and resident Kupffer cells in the liver. The latter may release
cytokines, such as IL-6, that stimulate hepcidin production by the hepatocytes. Prolonged hyper-hepcidinemia may then lead to iron sequestration in macrophages,
hypoferremia and iron-restricted anemia. In spite of low serum iron, tissue iron excess and inﬂammatory mediators lead to elevation of serum ferritin.
JOURNAL OF HEPATOLOGYunrestricted ﬂux of iron into the bloodstream followed by tissue
iron overload, with the potential for toxicity and damage. All these
conditions may beneﬁt from therapies based on hepcidin or hep-
cidin agonists (Table 2). Hereditary causes of hepcidin deﬁciency
are now classiﬁed within the hereditary hemochromatosis syn-
dromes, for simplicity, referred to as hemochromatosis (HC) [70]
(Table 1). Human HC has been associated with the common
C282Y polymorphism of HFE [71] or rare pathogenic mutations
of TfR2,[72] HJV [40], FPN [73] and HAMP itself [74]. All forms of
human HC are characterized by low or inadequate levels of hepci-
din [53,54,75,76]. In fact, HFE, TfR2, and HJV all appear to be inde-
pendent but complementary regulators of hepcidin synthesis in
the liver (Fig. 1). If the HAMP gene is intact and each of the three
regulators is functioning as it should, the amount of iron trans-
ferred into the blood will be appropriate to the body’s needs,
and excessive iron deposition in tissueswill be avoided. FunctionalJournal of Hepatology 201loss of one of the hepcidin regulators, depending on the different
roles of such a regulator in hepcidin transcription, will result in a
different effects on the actual level of circulating hormone and,
consequently, on the extent of plasma iron loading, tissue iron
excess, and the ultimate disease phenotype. The latter, will range
from the severe early onset HJV- and HAMP-associated forms to
the milder adult onset HFE and TfR2-associated forms. Fig. 2
shows the key pathogenic events associated with hepcidin deﬁ-
ciency in HFE-HC, themost common and paradigmatic form of HC.
With this scheme in mind, HC, like diabetes, appears essen-
tially as an endocrine disorder, caused by defective synthesis/
activity of the iron hormone hepcidin; therefore, HC is a human
disease that may beneﬁt of hormonal (hepcidin) therapy. Iron
overload in any form of HC can be readily managed in most
patients by therapeutic phlebotomy [77]. Phlebotomy can treat
and revert many symptoms and complications of HC, and provide1 vol. 54 j 173–181 177
Table 2. Hepcidin therapy in human iron disorders.
BMP, bone morphogenetic proteins; SMAD, Sma and mothers against decapentaplegic homolog; EPO, erythropoietin; ESA, erythropoiesis stimulating agents; TMPRSS6,
transmembrane serine protease 6 gene; IBD, inﬂammatory bowel disease; CKD, chronic kidney diseases.
Reviewnormal survival if initiated at early stages. However, patients
with underlying anemias, severe heart disease or reduced venous
access may not tolerate this form of treatment, and compliance
may also be variable over time [77]. Therefore, if phlebotomy is
contraindicated because of severe anemia, cardiac failure, or poor
tolerance, other therapeutic strategies, such as iron chelators can
be considered. However, neither phlebotomy nor iron chelators
represent true etiologic therapies of HC. Hormone replacement
could be an option in the future, in severe forms of the disease
or when no other strategies are possible. Long-acting hepcidin
peptides (which overcome the problem of the short-lived hepci-
din molecule in vivo) could be developed. Alternatively, the use of
hepcidin agonists could be a valuable strategy aimed at either
raising serum hepcidin levels, or favoring FPN internalization/
degradation. The former, could be achieved by targeting the
BMP/SMAD signaling pathway, the latter by using small-mole-
cules able to trigger the internalization, ubiquitination or degra-
dation of FPN. The ﬁrst approach has already shown some
potential in pre-clinical in vitro and in vivo settings. Supra-phys-
iological doses of exogenous BMP6 in Hfe/ mice were recently
able to overcome the impairment in the BMP–SMAD signaling
pathway and rescue hepcidin expression in Hfe/ hepatocytes
[56]. Moreover, in vivo administration of exogenous BMP6 for
10 days has improved hepcidin deﬁciency, and corrected serum
and tissue iron abnormalities in Hfe/ mice [78]. However,
longer treatment with exogenous BMP6 were unsuccessful
because of peritoneal calciﬁcations, consistent with the known
bone-inducing properties of BMP6 [78]. Thus, exogenous BMP6
administration in its current form is not a viable therapy. How-
ever, these data provide proof of concept that activators of the
BMP6–SMAD signaling pathway can be used to treat HC if more
speciﬁc therapies can be developed without bone inducing or
other off-target effects.
Similar strategies could be also applied to hereditary anemias
associated with inefﬁcient erythropoiesis, which, at early pre-
transfusion stages, are characterized by low hepcidin levels [79]
(likely caused by erythroid factors overproduced in the bone mar-
row), increased iron absorption, and excess hepatic iron deposi-
tion in periportal hepatocytes (Fig. 2).178 Journal of Hepatology 201Disorders potentially treatable with hepcidin antagonists
Any genetic or acquired factor that causes increased hepcidin
synthesis activity, will lead to decreased iron transfer into plasma
and hypoferremia. If hepcidin stimulation does persist, iron-
restricted erythropoiesis and anemia may follow. Three forms
of anemia exist that are associated with hepcidin abnormalities;
one common form: anemia of chronic disease (ACD); and two
rare forms: iron-refractory iron deﬁciency anemia (IRIDA) and
anemia associated with hepcidin-producing hepatic adenomas.
All these conditions may beneﬁt of therapies based on hepcidin
antagonists (Table 2).
Anemia of chronic diseases (ACD), or anemia of inﬂammation,
develops in the setting of infections and inﬂammatory disorders,
such as rheumatologic diseases, inﬂammatory bowel diseases,
chronic kidney disease (CKD), infections, and malignancies [80].
In a number of these pathologic conditions, elevated hepcidin
has been reported [81]. Even in disorders associated with mild
chronic inﬂammation, such as obesity, iron deﬁciency has been
associated with elevated hepcidin levels. In CKD, the cause of
anemia is clearly multifactorial: inadequate production of eryth-
ropoietin (likely the most important factor in the pathogenesis of
anemia, and the reason for treating CKD patients with erythro-
poietin stimulating agents, ESA) [82]; shortened erythrocyte sur-
vival; erythropoiesis-inhibitory effects of accumulating uremic
toxins; iron loss caused by blood trapping in the dialysis appara-
tus and repeated phlebotomy. Yet, some patients also have a
functional iron deﬁciency and reticuloendothelial cell iron block-
ade, with low levels of circulating iron that limit erythropoiesis.
This is likely due to high hepcidin levels induced by a chronic
inﬂammatory state (Fig. 2) [83]. Beyond inﬂammation, another
factor may contribute to increased hepcidin in CKD. Loss of kid-
ney function could decrease hepcidin clearance and lead to the
accumulation of hepcidin and the development of iron-restrictive
anemia [81]. Hyper-hepcidinemia may explain cases of hypore-
sponsiveness to therapeutic erythropoietin in CKD [84].
IRIDA is a hereditary hypochromic, microcytic anemia, refrac-
tory to treatment with oral iron, and only partially responsive to
parenteral iron. The molecular basis is increased hepcidin1 vol. 54 j 173–181
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production due to mutations in the hepcidin inhibitor TMPRSS6
[85,86] (Fig. 1). When TMPRSS6 is mutated, hepcidin expression
is increased, chronically inhibiting iron absorption and resulting
in the development of iron deﬁciency anemia. Another rare form
of hepcidin-linked anemia is associated with hepatic adenomas.
This picture was ﬁrst reported in the setting of type 1a glycogen
storage disease: the patients presented large hepatic adenomas
overproducing hepcidin, iron-deﬁciency microcytic anemia unre-
sponsive or partially responsive to iron [87]. Anemia was cured
after tumor resection. A patient with a similar presentation in
the setting of a large hepatic adenoma but no glycogen disease
has been also reported [88].
Several experimental therapeutic approaches have been
undertaken to target steps of hepcidin production or activity
(Box 2). In a mouse model of ACD caused by injections of Brucella
abortus, hepcidin antagonists (neutralizing monoclonal antibody
to hepcidin) were effective in treating anemia [89]. Other drugs
can interfere with the iron–BMP–SMAD signalling pathway.
Dorsomorphin, a small-molecule that selectively inhibits the
BMP type I receptors ALK2, ALK3, and ALK6 and thus blocks
BMP-mediated SMAD1/5/8 phosphorylation, was able to prevent
hepcidin induction by iron in vivo [32]. Soluble HJV, also acting as
an antagonist of BMP signaling, decreased hepcidin baseline
expression in mice and concurrently increased liver iron content
[33]. Furthermore, some existing anti-cytokine therapies may be
acting by decreasing hepcidin production induced by cytokines
during ACD. Tocilizumab, a humanized anti-interleukin-6 recep-
tor antibody currently used in rheumatoid arthritis, was shown
to improve anemia in monkey arthritis and patients with multi-
centric Castelman’s disease by suppressing IL-6-induced hepcidin
expression [90,91]. Large pharmacological doses of erythropoie-
tin (EPO) can sometimes overcome the resistance of ACD to
erythropoietin [84]. In fact, EPO injections in mice and humans
resulted in suppression of hepcidin production [92,93], and this
may be the mechanism by which high EPO levels overcome iron
restriction. In line with this EPO effect, ESA administration inhib-
its hepcidin expression both in the CKD population and the gen-
eral population. [94]. Recently, heparin and heparin-derivatives
have been reported to inhibit hepcidin transcription by inter-
fering with the BMP signaling pathway (Paolo Arosio, Milan,
personal communications).
BMP: bone morphogenetic proteins; FPN: ferroportin; IL6: inter-
leukin 6; EPO: erythropoietin; ESA: erythropoiesis stimulating
agents; HIF: hypoxia inducible factors.Journal of Hepatology 201Conclusions
In recent years, we have witnessed a dramatic progress in iron
metabolism research and our understanding of human iron disor-
ders has enormously improved. We have recognized hepcidin as
the key regulator of iron homeostasis and a central pathogenic
factor in a number of human diseases. We are now seeing medi-
cal applications of these advances. The notion that hepcidin
excess or decrease may contribute to the dysregulation of iron
homeostasis in hereditary and acquired iron disorders raises
the possibility that hepcidin-lowering or enhancing agents may
be an effective strategy for curing forms of anemia or iron excess,
respectively (Box 2). Some pre-clinical and clinical studies have
shown that hepcidin antibodies, BMP agonists or antagonists,
cytokine receptor antibodies, and small-molecules can modify
hepcidin expression and reverse iron abnormalities in vivo, in a
number of disease models. How far are we from using hepcidin
therapies? Due to the more profound understanding of patho-
genic mechanisms involved in hyper-hepcidinemia of inﬂamma-
tory states and a growing interest of pharmaceutical and biotech
companies in ACD, it is likely that hepcidin antagonists will be
the ﬁrst to hit the market. In fact, as discussed earlier, anti-IL6
antibodies inhibiting hepcidin in patients with rheumatologic
disorders and ACD are already in place. However, well-designed
clinical studies addressing safety and long-term efﬁcacy are still
needed in order to clarify the risks and beneﬁts of hepcidin-tar-
geted treatments. Yet, a new era has started in the treatment of
human disorders associated with iron disturbances. From the
naive and archaic approach of bleeding our patients to remove
iron excess or re-ﬁlling iron stores by using all kind of iron sup-
plements, we are now moving to the development of intelligent
molecular therapies able to modify iron entrance into the body,
iron release from tissues or even iron movements within cells
and organelles. This may offer new tools to treat or complement
the treatment of a number of human disorders associated with
iron excess, deﬁciency or misdistribution.Acknowledgement
Grant support: This paper was supported by the PRIN 2008 Grant
from the Italian National Research Council and Telethon grant
GGP10233.Conﬂict of interest
The author declared that he does not have anything to disclose
regarding funding or conﬂict of interest with respect to thismanu-
script. The author does not have a relationship with the manu-
facturers of the drugs involved either in the past or present and
did not receive funding from the manufacturers to carry out his
research.
References
[1] Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P,
et al. LEAP-1, a novel highly disulﬁde-bonded human peptide, exhibits
antimicrobial activity. FEBS Lett 2000;480 (2–3):147–150.
[2] Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial
peptide synthesized in the liver. J Biol Chem 2001;276 (11):7806–7810.
[3] Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new
mouse liver-speciﬁc gene, encoding a protein homologous to human1 vol. 54 j 173–181 179
Review
antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol
Chem 2001;276 (11):7811–7819.
[4] Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al.
Lack of hepcidin gene expression and severe tissue iron overload in
upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci
USA 2001;98 (15):8780–8785.
[5] Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, et al. C/
EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial
peptide and regulator of iron metabolism. Cross-talk between C/EBP
pathway and iron metabolism. J Biol Chem 2002;277 (43):41163–41170.
[6] Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al.
Severe iron deﬁciency anemia in transgenic mice expressing liver hepcidin.
Proc Natl Acad Sci USA 2002;99 (7):4596–4601.
[7] Bothwell TH. The control of iron absorption. Br J Haematol 1968;14
(5):453–456.
[8] Bothwell TH, Hurtado AV, Donohue DM, Finch CA. Erythrokinetics. IV. The
plasma iron turnover as a measure of erythropoiesis. Blood 1957;12
(5):409–427.
[9] Finch CA. Iron Balance in Man. Nutr Rev 1965;23:129–131.
[10] Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology
2007;46 (4):1291–1301.
[11] Valore EV, Ganz T. Posttranslational processing of hepcidin in human
hepatocytes is mediated by the prohormone convertase furin. Blood Cells
Mol Dis 2008;40 (1):132–138.
[12] Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in
intracellular iron metabolism. J Biol Chem 2000;275 (26):19906–19912.
[13] Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al.
Positional cloning of zebraﬁsh ferroportin1 identiﬁes a conserved vertebrate
iron exporter. Nature 2000;403 (6771):776–781.
[14] McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel
duodenal iron-regulated transporter, IREG1, implicated in the basolateral
transfer of iron to the circulation. Mol Cell 2000;5 (2):299–309.
[15] Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al.
Hepcidin regulates cellular iron efﬂux by binding to ferroportin and inducing
its internalization. Science 2004;306 (5704):2090–2093.
[16] Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of
hepcidin is essential for its interaction with ferroportin: structure-function
study. Blood 2006;107 (1):328–333.
[17] De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI,
et al. The molecular mechanism of hepcidin-mediated ferroportin down-
regulation. Mol Biol Cell 2007;18 (7):2569–2578.
[18] Vecchi C, Montosi G, Zhang K, Lamberti I, Duncan SA, Kaufman RJ, et al. ER
stress controls iron metabolism through induction of hepcidin. Science
2009;325 (5942):877–880.
[19] Oliveira SJ, Pinto JP, Picarote G, Costa VM, Carvalho F, Rangel M, et al. ER
stress-inducible factor CHOP affects the expression of hepcidin by modu-
lating C/EBPalpha activity. PLoS One 2009;4 (8):e6618.
[20] Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene
encoding the iron regulatory peptide hepcidin is regulated by anemia,
hypoxia, and inﬂammation. J Clin Invest 2002;110 (7):1037–1044.
[21] Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase
VH, et al. Regulation of iron homeostasis by the hypoxia-inducible
transcription factors (HIFs). J Clin Invest 2007;117 (7):1926–1932.
[22] Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, et al.
Erythropoietin mediates hepcidin expression in hepatocytes through EPOR
signaling and regulation of C/EBPalpha. Blood 2008;111 (12):
5727–5733.
[23] Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of
GDF15 in thalassemia suppress expression of the iron regulatory protein
hepcidin. Nat Med 2007;13 (9):1096–1101.
[24] Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al.
Identiﬁcation of TWSG1 as a second novel erythroid regulator of hepcidin
expression in murine and human cells. Blood 2009;114 (1):181–186.
[25] Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, et al. The serine protease
TMPRSS6 is required to sense iron deﬁciency. Science 2008;320
(5879):1088–1092.
[26] Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The
serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by
cleaving membrane hemojuvelin. Cell Metab 2008;8 (6):502–511.
[27] Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6
mediates hypoferremia of inﬂammation by inducing the synthesis of the
iron regulatory hormone hepcidin. J Clin Invest 2004;113 (9):
1271–1276.
[28] Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression
through STAT3. Blood 2006;108 (9):3204–3209.180 Journal of Hepatology 201[29] Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW,
Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its
inﬂammatory stimulation. Blood 2007;109 (1):353–358.
[30] Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3
is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gas-
troenterology 2007;132 (1):294–300.
[31] Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, et al. A role of SMAD4 in iron
metabolism through the positive regulation of hepcidin expression. Cell
Metab 2005;2 (6):399–409.
[32] Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al.
Dorsomorphin inhibits BMP signals required for embryogenesis and iron
metabolism. Nat Chem Biol 2008;4 (1):33–41.
[33] Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone
morphogenetic protein signaling in vivo regulates systemic iron balance. J
Clin Invest 2007;117 (7):1933–1939.
[34] Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone
morphogenetic protein (BMP)-responsive element in the hepcidin promoter
controls HFE2-mediated hepatic hepcidin expression and its response to IL-6
in cultured cells. J Mol Med 2008;86 (5):531–540.
[35] Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, et al.
Endoplasmic reticulum stress activates cleavage of CREBH to induce a
systemic inﬂammatory response. Cell 2006;124 (3):587–599.
[36] Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ. Regulation of hepcidin
and ferroportin expression by lipopolysaccharide in splenic macrophages.
Blood Cells Mol Dis 2005;35 (1):47–56.
[37] Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine
formation of hepcidin induces iron retention in human monocytes. Blood
2008;111 (4):2392–2399.
[38] De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, et al.
Hepcidin mediates transcriptional changes that modulate acute cytokine-
induced inﬂammatory responses in mice. J Clin Invest 2010;120
(7):2395–2405.
[39] Corradini E, Babitt JL, Lin HY. The RGM/DRAGON family of BMP co-receptors.
Cytokine Growth Factor Rev 2009;20 (5–6):389–398.
[40] Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube
MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked
juvenile hemochromatosis. Nat Genet 2004;36 (1):77–82.
[41] Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by
soluble and cell-associated hemojuvelin. Blood 2005;106 (8):2884–2889.
[42] Zhang AS, West Jr AP, Wyman AE, Bjorkman PJ, Enns CA. Interaction of
hemojuvelin with neogenin results in iron accumulation in human embry-
onic kidney 293 cells. J Biol Chem 2005;280 (40):33885–33894.
[43] Yang F, West Jr AP, Allendorph GP, Choe S, Bjorkman PJ. Neogenin interacts
with hemojuvelin through its two membrane-proximal ﬁbronectin type III
domains. Biochemistry 2008;47 (14):4237–4245.
[44] Lee DH, Zhou LJ, Zhou Z, Xie JX, Jung JU, Liu Y, et al. Neogenin inhibits HJV
secretion and regulates BMP induced hepcidin expression and iron homeo-
stasis. Blood 2010;115:3136–3145.
[45] Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin
expression via a selective subset of BMP ligands and receptors indepen-
dently of neogenin. Blood 2008;111 (10):5195–5204.
[46] Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone
morphogenetic protein signaling by hemojuvelin regulates hepcidin expres-
sion. Nat Genet 2006;38 (5):531–539.
[47] Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, et al. Iron
regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6,
Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008;112 (4):1503–1509.
[48] Mleczko-Sanecka K, Casanovas G, Ragab A, Breitkopf K, Muller A, Boutros M,
et al. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin
expression. Blood 2010;115 (13):2657–2665.
[49] Andriopoulos Jr B, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al.
BMP6 is a key endogenous regulator of hepcidin expression and iron
metabolism. Nat Genet 2009;41 (4):482–487.
[50] Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP.
Lack of the bone morphogenetic protein BMP6 induces massive iron
overload. Nat Genet 2009;41 (4):478–481.
[51] Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, Watson N, et al. The
hemochromatosis gene product complexes with the transferrin receptor and
lowers its afﬁnity for ligand binding. Proc Nat Acad Sci USA 1998;95
(4):1472–1477.
[52] Ahmad KA, Ahmann JR, Migas MC, Waheed A, Britton RS, Bacon BR, et al.
Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells
Mol Dis 2002;29 (3):361–366.
[53] Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al.
Disrupted hepcidin regulation in HFE-associated haemochromatosis and the1 vol. 54 j 173–181
JOURNAL OF HEPATOLOGY
liver as a regulator of body iron homoeostasis. Lancet 2003;361
(9358):669–673.
[54] Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Veltkamp C, et al.
Expression of hepcidin in hereditary hemochromatosis: evidence for a
regulation in response to the serum transferrin saturation and to non-
transferrin-bound iron. Blood 2003;102 (1):371–376.
[55] Vujic Spasic M, Kiss J, Herrmann T, Galy B, Martinache S, Stolte J, et al. Hfe
acts in hepatocytes to prevent hemochromatosis. Cell Metab 2008;7
(2):173–178.
[56] Corradini E, Garuti C, Montosi G, Ventura P, Andriopoulos Jr B, Lin HY, et al.
Bonemorphogenetic protein signaling is impaired in an HFE knockout mouse
model of hemochromatosis. Gastroenterology 2009;137 (4):1489–1497.
[57] Kautz L, Meynard D, Besson-Fournier C, Darnaud V, Al Saati T, Coppin H,
et al. BMP/Smad signaling is not enhanced in Hfe-deﬁcient mice despite
increased Bmp6 expression. Blood 2009;114 (12):2515–2520.
[58] Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O’Kelly J, et al. Expression
of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype
of hereditary hemochromatosis. Blood 2005;105 (1):376–381.
[59] Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased
in TFR2-Hemochromatosis. Blood 2005;105:1803–1806.
[60] Grifﬁths WJ, Cox TM. Co-localization of the mammalian hemochromatosis
gene product (HFE) and a newly identiﬁed transferrin receptor (TfR2) in
intestinal tissue and cells. J Histochem Cytochem 2003;51 (5):
613–624.
[61] Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, inter-
action with transferrin receptor 2 suggests a molecular mechanism for
mammalian iron sensing. J Biol Chem 2006;281 (39):28494–28498.
[62] Waheed A, Britton RS, Grubb JH, Sly WS, Fleming RE. HFE association with
transferrin receptor 2 increases cellular uptake of transferrin-bound iron.
Arch Biochem Biophys 2008;474 (1):193–197.
[63] Chen J, Chloupkova M, Gao J, Chapman-Arvedson TL, Enns CA. HFE
modulates transferrin receptor 2 levels in hepatoma cells via interactions
that differ from transferrin receptor 1-HFE interactions. J Biol Chem
2007;282 (51):36862–36870.
[64] Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The
transferrin receptor modulates hfe-dependent regulation of hepcidin
expression. Cell Metab 2008;7 (3):205–214.
[65] Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J
Hematol 2007;82 (Suppl. 12):1142–1146.
[66] Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F,
et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic
GAA triplet repeat expansion. Science 1996;271 (5254):1423–1427.
[67] Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, et al.
Hepcidin is down-regulated in alcoholic liver injury: implications for the
pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006;30
(1):106–112.
[68] Harrison-Findik DD, Schafer D, Klein E, Timchenko NA, Kulaksiz H, Clemens
D, et al. Alcohol metabolism-mediated oxidative stress down-regulates
hepcidin transcription and leads to increased duodenal iron transporter
expression. J Biol Chem 2006;281 (32):22974–22982.
[69] Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, et al.
Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in
mice by reducing hepcidin transcription. Gastroenterology 2008;134
(1):226–238.
[70] Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis and
treatment. Gastroenterology 2010;139:393–408.
[71] Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A
novel MHC class I-like gene is mutated in patients with hereditary
haemochromatosis. Nat Genet 1996;13 (4):399–408.
[72] Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The
gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.
Nat Genet 2000;25 (1):14–15.
[73] Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH,
et al. A mutation in SLC11A3 is associated with autosomal dominant
hemochromatosis. Nat Genet 2001;28 (3):213–214.Journal of Hepatology 201[74] Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al.
Mutant antimicrobial peptide hepcidin is associated with severe juvenile
hemochromatosis. Nat Genet 2003;33 (1):21–22.
[75] Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased
in TFR2 hemochromatosis. Blood 2005;105 (4):1803–1806.
[76] Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V,
et al. The effects of erythropoetic activity and iron burden on hepcidin
expression in patients with thalassemia major. Haematologica 2006;91
(6):809–812.
[77] EASL. EASL Clinical Practice Guidelines on Hemochromatosis. J Hepatol 2010.
[78] Corradini E, Schmidt PJ, Meynard D, Garuti C, Montosi G, Chen S, et al. BMP6
treatment compensates for the molecular defect and ameliorates hemo-
chromatosis in Hfe knockout mice. Gastroenterology 2010. doi:10.1053/
j.gastro.2010.07.044.
[79] Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al.
Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer
2007;48 (1):57–63.
[80] Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys
Acta 2009;1790 (7):682–693.
[81] Nemeth E. Targeting the hepcidin–ferroportin axis in the diagnosis and
treatment of anemias. Adv Hematol 2010;2010:750643.
[82] Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications
for the anemia of CKD. Am J Kidney Dis 2010;55 (4):726–741.
[83] Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al.
Hepcidin–a potential novel biomarker for iron status in chronic kidney
disease. Clin J Am Soc Nephrol 2009;4 (6):1051–1056.
[84] Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes
and management. Adv Chronic Kidney Dis 2009;16 (2):94–100.
[85] Melis MA, Cau M, Congiu R, Sole G, Barella S, Cao A, et al. A mutation in the
TMPRSS6 gene, encoding a transmembrane serine protease that suppresses
hepcidin production, in familial iron deﬁciency anemia refractory to oral
iron. Haematologica 2008;93 (10):1473–1479.
[86] Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR,
et al. Mutations in TMPRSS6 cause iron-refractory iron deﬁciency anemia
(IRIDA). Nat Genet 2008;40 (5):569–571.
[87] Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC.
Inappropriate expression of hepcidin is associated with iron refractory
anemia: implications for the anemia of chronic disease. Blood 2002;100
(10):3776–3781.
[88] Chung A, Leo K, Wong G, Chuah K, Ren J, Lee C. Giant hepatocellular
adenoma presenting with chronic iron deﬁciency anemia. Am J Gastroen-
terol 2006;101 (9):2160–2162.
[89] Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. Anti-
hepcidin antibody treatment modulates iron metabolism and is effective in a
mouse model of inﬂammation-induced anemia. Blood 2010;115:
3616–3624.
[90] Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M. Tocilizumab, a
humanized anti-interleukin-6 receptor antibody, improved anemia in
monkey arthritis by suppressing IL-6-induced hepcidin production. Rheu-
matol Int 2010;30 (7):917–923.
[91] Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-
interleukin 6 receptor antibody tocilizumab reduces the level of serum
hepcidin in patients with multicentric Castleman’s disease. Haematologica
2007;92 (6):857–858.
[92] Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al.
Erythropoietin administration in humans causes a marked and pro-
longed reduction in circulating hepcidin. Haematologica 2010;95
(3):505–508.
[93] Huang H, Constante M, Layoun A, Santos MM. Contribution of STAT3 and
SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood
2009;113 (15):3593–3599.
[94] Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum
hepcidin concentration in chronic haemodialysis patients: associations and
effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest
2009;39:883–890.1 vol. 54 j 173–181 181
